Provided by Tiger Trade Technology Pte. Ltd.

Tyra Biosciences, Inc.

20.43
-0.5800-2.76%
Post-market: 20.430.00000.00%19:30 EDT
Volume:1.05M
Turnover:21.43M
Market Cap:1.40B
PE:-8.50
High:21.39
Open:21.25
Low:20.17
Close:21.01
52wk High:40.65
52wk Low:12.98
Shares:68.76M
Float Shares:40.01M
Volume Ratio:1.12
T/O Rate:2.62%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.4031
EPS(LYR):-2.0125
ROE:-45.31%
ROA:-28.46%
PB:3.97
PE(LYR):-10.15

Loading ...

Tyra Biosciences Q2 FY26 Net Loss Widens to $45.56 Million; R&D Expenses Climb to $39.2 Million

Reuters
·
Aug 05

Tyra Biosciences Advances TYRA-200 Into First-in-Human FGFR2 Cancer Trial

TIPRANKS
·
Jul 30

Analyst Maintains Buy on Tyra Biosciences, Reiterates $50 Price Target on NMIBC Opportunity

TIPRANKS
·
Jul 22

Analysts Are Bullish on These Healthcare Stocks: Tyra Bioscience (TYRA), Eli Lilly & Co (LLY)

TIPRANKS
·
Jul 19

Tyra Biosciences: Buy Rating Reaffirmed, $50 Price Target Maintained on Strong Dabogratinib Potential

TIPRANKS
·
Jul 15

Tyra Biosciences Initiated at Buy by Jones Trading

Dow Jones
·
Jun 17

Tyra Biosciences initiated with a Buy at JonesResearch

TIPRANKS
·
Jun 17

Tyra Biosciences Inc : Jonestrading Initiates Coverage With Buy Rating; Target Price $56

THOMSON REUTERS
·
Jun 17

Analysts Offer Insights on Healthcare Companies: Spyre Therapeutics (SYRE) and Tyra Bioscience (TYRA)

TIPRANKS
·
Jun 16

Tyra Biosciences' Weak Investor Sentiment Reflects Macro Pressures, Renewed SURF-302 Concerns, BofA Says

MT Newswires Live
·
Jun 10

Tyra Biosciences Is Maintained at Buy by B of A Securities

Dow Jones
·
Jun 10

Tyra Biosciences price target raised to $42 from $37 at BofA

TIPRANKS
·
Jun 10

Jazz Pharmaceuticals : Bofa Global Research Raises Price Objective to $307.00 From $281.00

THOMSON REUTERS
·
Jun 10

Tyra Biosciences : Bofa Global Research Raises Price Objective to $42.00 From $37.00

THOMSON REUTERS
·
Jun 10

Analyst Initiates Buy on Tyra Biosciences, Citing De-Risked Dabogratinib Program and Attractive Entry Ahead of Key Bladder Cancer Data

TIPRANKS
·
Jun 10

Barclays Keeps Their Buy Rating on Tyra Bioscience (TYRA)

TIPRANKS
·
Jun 03

Tyra Biosciences Shareholders Reelect Directors and Ratify Auditor

TIPRANKS
·
Jun 03

Tyra Biosciences stockholders elect three Class II directors at annual meeting

Reuters
·
Jun 03

Tyra Biosciences Rated Buy on Anticipation of Interim SURF302 Dabogratinib Data in FGFR3‑Driven NMIBC

TIPRANKS
·
May 26

Assessing Tyra Biosciences (TYRA) Valuation After Wider Losses And Progress In Dabogratinib Trials

Simply Wall St.
·
May 21